Unlocking the potential of serpin biology to treat chronic and devastating fibrotic and inflammatory diseases of aging.
MDI Therapeutics is a biotechnology company focused on developing novel serine protease-based therapies (“Serpins”) for the treatment of fibrosis and fibroproliferative disorders. MDI has developed deep proprietary expertise in the biology of Serpins, a class of proteins associated with coronary heart disease, thrombosis, and chronic fibrotic and inflammatory diseases. Serpins have historically been a challenging target for pharmaceutical development, but MDI has shown that they can successfully use their proprietary high throughput screening platform to find novel drug candidates.
The company was founded at the University of Michigan by Dr. Daniel A. Lawrence, PhD, Professor of Cardiovascular Medicine. MDI’s lead program is a first-in-class orally available plasminogen activator inhibitor-1 (PAI-1)inhibitor. Extensive scientific evidence points clearly to PAI-1’s involvement in fibrosis and thrombosis. By successfully targeting PAI-1, MDI aims to provide a powerful new tool for the treatment of these common and devastating diseases of aging.